Economic appraisal of maintenance patenteral iron administration in treatment of anaemia in chronic haemodialysis patients

Nephrology Dialysis Transplantation

Volumn 11, Issue 2, 1996, Pages 319-322

  Sepandj, F ^a,b   Jindal, K ^a   West, M ^a   Hirsch, D ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Anaemia; Ferritin; Ferrous sulphate; Haemodialysis; Intravenous iron dextran complex; Recombinant human erythropoietin

Indexed keywords

FERRITIN; FERROUS SULFATE; HEMOGLOBIN; IRON DEXTRAN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG COST; DRUG MONITORING; ECONOMIC ASPECT; FEMALE; FERRITIN BLOOD LEVEL; HEMODIALYSIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; IRON STORAGE; IRON THERAPY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADULT; AGED; ANEMIA, IRON-DEFICIENCY; COSTS AND COST ANALYSIS; ERYTHROPOIETIN; FEMALE; HEMATINICS; HUMANS; INFUSIONS, INTRAVENOUS; IRON-DEXTRAN COMPLEX; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; RENAL DIALYSIS;

EID: 0030043814     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.ndt.a027260     Document Type: Article

References (14)

1. Eschbach JW, Cook JD, Scribner BH et al. Iron balance in haemodialysis patients. Arch Intern Med 1977; 87: 710-713
2. Forth W, Rummel W. Iron absorption. Physiol Rev 1973; 53: 724-729
3. Van Wyck DB. Iron management during recombinant human erythropoietin therapy. Am J Kidner Dis 1989; 14 2 [Suppl 1]: 9-13
4. Van Wyck DB, Stivelman JC, Ruiz J et al. Iron status in patients receiving erythropoietin for dialysis associated anaemia. Kidney Int 1989; 35: 712-716
5. MacDougall AC, Hutton RD, Cavill I, Coles GA, Williams JD. Poor response to treatment of renal anaemia with erythropoietin corrected by iron given intravenously. Br Med J 1989; 299: 157-158
6. Van Wyck DB. Iron dextran in chronic renal failure. Semin Dial 1991; 4,2: 112-114
7. Eschbach JW, Cook JD, Finch CA. Iron absorption in chronic renal disease. Clin Sci 1970; 38: 191-196
8. Gokal R, Millard PR, Weatherall DJ et al. Iron metabolism in hemodialysis patients: a study of the management of iron therapy and overload. Q J Med 1979; 48: 369-391
9. Bonnar J, Goldberg A, Smith JA. Do pregnant women take their own iron? Lancet 1969; 1: 457-458
10. Schaefer RM, Schaefer L. Management of iron substitution during rHuEpo therapy in chronic renal failure patients. Erythropoiesis 1992; 3: 71-75
11. Sunder-Plassmann G, Hoerl WH. Iron metabolism and iron substitution during erythropoietin therapy. Clin Invest (in press)
12. Stevens ME, Summerfield GP, Hall AA et al. Cost benefits of low dose subcutaneous erythropoietin in patients with anaemia of end stage renal disease. Br Med J 1992; 304: 474-477
13. Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Br Med J 1990; 300. 573-578
14. Sheingold S, Churchill D, Murihead N, et al. The impact of recombinant human erythropoietin on medical care costs for hemodialysis patients in Canada. Soc Sci Med 1992; 34: 9: 983-991